NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that revenues for the third quarter rose 3 percent year over year as it narrowly beat the consensus Wall Street estimates on the top and bottom lines.

The company took in $3.19 billion in total revenues for the three months ended Sept. 28, up from $3.09 billion a year ago, and edging out the average analyst estimate of $3.18 billion. Organically, revenues grew 2 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.